NYSE:PEN

Penumbra - PEN Stock Forecast, Price & News

$189.60

-2.22 (-1.16%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $189.39
▼
$198.65
50-Day Range: $129.38
▼
$205.88
52-Week Range: $114.86
▼
$290.36

Volume: 266,049 shs
Average Volume: 381,966 shs
Market Capitalization: $7.18 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $228.90

Penumbra MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 20.7% Upside
$228.90 Price Target
Short Interest: Bearish
6.09% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.89
Upright™ Environmental Score
News Sentiment: 0.31
Based on 5 Articles This Week
Insider Trading: Selling Shares
$1.37 M Sold Last Quarter
Proj. Earnings Growth: 352.00%
From $0.25 to $1.13 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

278th out of 1,095 stocks

Surgical & Medical Instruments Industry

33rd out of 106 stocks

3.5

Analyst's Opinion

Consensus Rating
Penumbra has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $228.90, Penumbra has a forecasted upside of 20.7% from its current price of $189.60.
Amount of Analyst Coverage
Penumbra has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
6.09% of the float of Penumbra has been sold short.
Short Interest Ratio / Days to Cover
Penumbra has a short interest ratio ("days to cover") of 5.5.
Change versus previous month
Short interest in Penumbra has recently increased by 4.31%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Penumbra does not currently pay a dividend.
Dividend Growth
Penumbra does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Penumbra has received a 54.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Surgical instruments" product. See details.
Environmental Sustainability
The Environmental Impact score for Penumbra is -0.89.

2.4

News and Social Media Coverage

News Sentiment
Penumbra has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Penumbra this week, compared to 3 articles on an average week.
Search Interest
Only 4 people have searched for PEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
4 people have added Penumbra to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,368,163.00 in company stock.
Percentage Held by Insiders
Only 5.50% of the stock of Penumbra is held by insiders.
Percentage Held by Institutions
81.65% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Penumbra are expected to grow by 352.00% in the coming year, from $0.25 to $1.13 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Penumbra is -364.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Penumbra is -364.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Penumbra has a P/B Ratio of 7.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Penumbra (NYSE:PEN) Stock

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Stock News Headlines

October 2, 2022 | washingtonpost.com

A different kind of separation anxiety during my wife's business trip - The Washington Post

September 30, 2022 | americanbankingnews.com

Penumbra, Inc. (NYSE:PEN) Given Average Rating of "Moderate Buy" by Analysts

September 30, 2022 | americanbankingnews.com

Penumbra, Inc. (NYSE:PEN) Receives $228.90 Consensus PT from Brokerages

September 28, 2022 | marketwatch.com

Thrombectomy Devices Market to show impressive growth of 7.31% CAGR during the period 2022-2027 | 125 Report Pages

September 26, 2022 | finance.yahoo.com

Penumbra Stock Hits 80-Plus Relative Strength Rating Benchmark

September 25, 2022 | americanbankingnews.com

Penumbra (NYSE:PEN) Stock Price Up 1.5%

September 22, 2022 | finance.yahoo.com

Penumbra Ramps Up Efforts To Launch Indigo Aspiration System In Japan

September 22, 2022 | businesswire.com

Penumbra and Asahi Intecc Partner With Goal of Introducing Indigo™ System Including Lightning™ Intelligent Aspiration to Japan - Business Wire

September 22, 2022 | finance.yahoo.com

Penumbra and Asahi Intecc Partner With Goal of Introducing Indigo™ System Including Lightning™ Intelligent Aspiration to Japan

September 9, 2022 | finance.yahoo.com

Penumbra (PEN) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance

September 9, 2022 | benzinga.com

Penumbra (NYSE:PEN) – Expert Ratings for Penumbra - Benzinga

September 9, 2022 | nasdaq.com

Penumbra (PEN) Surges 6.2%: Is This an Indication of Further Gains? - Nasdaq

September 9, 2022 | benzinga.com

What 5 Analyst Ratings Have To Say About Penumbra

September 8, 2022 | nasdaq.com

PEN Makes Bullish Cross Above Critical Moving Average - Nasdaq

September 8, 2022 | finance.yahoo.com

Penumbra Announces European Launch of RED® Reperfusion Catheters for Stroke Care - Yahoo Finance

September 7, 2022 | businesswire.com

Penumbra Announces European Launch of RED® Reperfusion Catheters for Stroke Care - Business Wire

September 2, 2022 | reuters.com

SGS acquires Penumbra Security, expanding U.S. footprint - Reuters.com

August 30, 2022 | finance.yahoo.com

The Global Transcatheter Embolization & Occlusion Device Market grew USD 8,467.01 million by 2027, at a CAGR of 12.34%. - Yahoo Finance

August 25, 2022 | businesswire.com

Latest Data Demonstrates Penumbra System and RED® Reperfusion Catheters Effective for Broad Stroke Care - Business Wire

August 25, 2022 | finance.yahoo.com

Latest Data Demonstrates Penumbra System and RED® Reperfusion Catheters Effective for Broad Stroke Care

August 24, 2022 | finance.yahoo.com

Penumbra, Inc. to Present at Upcoming Investor Conferences - Yahoo Finance

August 24, 2022 | finance.yahoo.com

Penumbra, Inc. to Present at Upcoming Investor Conferences

August 18, 2022 | msn.com

10 Easiest Survival Video Games For New Players

August 18, 2022 | msn.com

Penumbra Earnings Perspective: Return On Invested Capital

August 10, 2022 | ft.com

Chinese technology in the 'Internet of Things' poses a new threat to the west - Financial Times

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Company Calendar

Last Earnings: 8/04/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:PEN
CUSIP: N/A
CIK: 1321732
Web: www.penumbrainc.com
Phone: (510) 748-3200
Fax: 510-748-3232
Employees: 3,800
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $228.90
High Stock Price Forecast: $300.00
Low Stock Price Forecast: $163.00
Forecasted Upside/Downside: +20.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 758.40
P/E Growth: N/A
Net Income: $5.28 million
Net Margins: -2.40%
Pretax Margin: -4.89%
Return on Equity: 0.97%
Return on Assets: 0.71%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 4.93
Quick Ratio: 2.90

Sales & Book Value

Annual Sales: $747.59 million
Price / Sales: 9.61
Cash Flow: $1.13 per share
Price / Cash Flow: 167.72
Book Value: $25.53 per share
Price / Book: 7.43

Miscellaneous

Outstanding Shares: 37,890,000
Free Float: 35,804,000
Market Cap: $7.18 billion
Optionable: Optionable
Beta: 0.66

Key Executives

Mr. Adam Elsesser (Age 60)
Co-Founder, Chairman, Pres & CEO
Comp: $497.79k

Dr. Arani Bose M.D. (Age 60)
Co-Founder & Director

Ms. Maggie S. Yuen (Age 50)
Chief Financial Officer
Comp: $616.3k

Mr. Lambert Shiu (Age 42)
Chief Accounting Officer
Comp: $468.76k

Ms. Johanna Roberts (Age 50)
Exec. VP, Gen. Counsel & Sec.
Comp: $608.84k

Ms. Lynn Rothman (Age 61)
Exec. VP & Chief Bus. Officer
Comp: $605.5k

Mr. Ben Sorci
Exec. VP of Operations

Mr. Pankaj Tiwari
Exec. VP & Chief Information Officer

Ms. Jee Hamlyn-Harris
Investor Relations Officer

Ms. Shruthi Narayan
Director of Marketing - Vascular

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PEN Stock - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PEN shares.
View PEN analyst ratings or view top-rated stocks.
What is Penumbra's stock price forecast for 2022?: 9 brokerages have issued 12-month price targets for Penumbra's shares. Their PEN share price forecasts range from $163.00 to $300.00. On average, they anticipate the company's share price to reach $228.90 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price.
View analysts price targets for PEN or view top-rated stocks among Wall Street analysts.
How have PEN shares performed in 2022?: Penumbra's stock was trading at $287.32 at the start of the year. Since then, PEN stock has decreased by 34.0% and is now trading at $189.60.
View the best growth stocks for 2022 here.
When is Penumbra's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our PEN earnings forecast.
How were Penumbra's earnings last quarter?: Penumbra, Inc. (NYSE:PEN) issued its quarterly earnings results on Thursday, August, 4th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.08. The company earned $208.30 million during the quarter, compared to the consensus estimate of $206.24 million. Penumbra had a negative net margin of 2.40% and a positive trailing twelve-month return on equity of 0.97%. Penumbra's revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.21 EPS.
What guidance has Penumbra issued on next quarter's earnings?: Penumbra updated its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $860.00 million-$875.00 million, compared to the consensus revenue estimate of $869.01 million.

What is Adam Elsesser's approval rating as Penumbra's CEO?: 57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.
What other stocks do shareholders of Penumbra own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).
What is Penumbra's stock symbol?: Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."
How do I buy shares of Penumbra?: Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Penumbra's stock price today?: One share of PEN stock can currently be purchased for approximately $189.60.
How much money does Penumbra make?: Penumbra (NYSE:PEN) has a market capitalization of $7.18 billion and generates $747.59 million in revenue each year. The company earns $5.28 million in net income (profit) each year or ($0.52) on an earnings per share basis.
How many employees does Penumbra have?: The company employs 3,800 workers across the globe.
How can I contact Penumbra?: Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232.

This page (NYSE:PEN) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Penumbra - PEN Stock Forecast, Price & News

Penumbra MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows